Sun Pharma shares jump 5% as India's largest drugmaker to buy U.S. firm Organon

To fuel its global ambitions, Sun Pharmaceutical Industries will acquire New Jersey-based Organon & Co in an all-cash deal that values the U.S. company at $11.75 billion.

Sun Pharmaceutical Industries will acquire Organon & Co in an all-cash deal valued at $11.75 billion, including debt. The acquisition is expected to be completed by the end of 2024, subject to regulatory approvals. Organon & Co has a portfolio of 60 medicines and a presence in over 140 markets worldwide. The company's revenue was $6.2 billion in 2022, with a net income of $1.2 billion.

The acquisition will directly impact the pharmaceutical industry's job market, as Sun Pharmaceutical Industries expands its global presence. The deal may lead to increased competition in the market, potentially affecting prices of certain medicines. As a result, pharmaceutical companies may need to reassess their strategies to remain competitive. This could lead to a shift in the industry's landscape.

The acquisition is part of a larger trend of consolidation in the pharmaceutical industry, with several major deals taking place in recent years. Sun Pharmaceutical Industries has been expanding its global presence through strategic acquisitions, and this deal marks a significant milestone in its growth strategy. The company's chairman, Israel Makov, has stated that the acquisition will help Sun Pharmaceutical Industries become a top-10 pharmaceutical company globally. This deal is a significant step towards achieving that goal.

The acquisition is subject to regulatory approvals, and the companies expect to complete the deal by the end of 2024. Investors should watch for the release of Sun Pharmaceutical Industries' quarterly earnings report, which will provide more insight into the company's financial performance and the impact of the acquisition. The deal is expected to be accretive to Sun Pharmaceutical Industries' earnings per share, with the company anticipating significant cost savings and revenue synergies. Interestingly, Organon & Co was spun off from Merck & Co in 2021, and this acquisition marks a significant change in its ownership structure just two years later.